Role in PharmNovo: Clinical outsourcing lead.
Company: WIN Outsourcing Consult.
Resumé: Rikke is highly specialized and globally experienced within Pre-clinical and Clinical R&D, Business Development and Contract/Outsourcing Management and has worked in the CRO and Pharmaceutical industry within these fields for more than 25 years.
For almost two decades, she headed up the R&D Outsourcing & Contracts Management R&D function at Lundbeck where she was globally responsible for all R&D outsourcing matters covering contractual, operational and relationship related activities with all CROs/vendors as well as complex research collaborations agreements with academia. Rikke has significant experience in developing and executing a broad variety of outsourcing strategies and is a strong negotiator with a win-win approach to retaining positive relationships with all stakeholders.
Prior to her employment at Lundbeck, Rikke worked for five years within bio-analytical research and clinical development in hospital/academia settings. This was followed by four years of employment in a larger CRO (International Project Manager followed by setting up the CRO’s first South East Asia office working as Business Development Manager and Line Manager in Singapore).
Rikke has since 2013 been a Steering Committee member of the Pharmaceutical Contract Management Group (PCMG.org.uk) in Europe.
Member of:
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read morePharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read moreAs the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more